Literature DB >> 20379207

The emerging mechanisms of isoform-specific PI3K signalling.

Bart Vanhaesebroeck1, Julie Guillermet-Guibert, Mariona Graupera, Benoit Bilanges.   

Abstract

Phosphoinositide 3-kinases (PI3Ks) function early in intracellular signal transduction pathways and affect many biological functions. A further level of complexity derives from the existence of eight PI3K isoforms, which are divided into class I, class II and class III PI3Ks. PI3K signalling has been implicated in metabolic control, immunity, angiogenesis and cardiovascular homeostasis, and is one of the most frequently deregulated pathways in cancer. PI3K inhibitors have recently entered clinical trials in oncology. A better understanding of how the different PI3K isoforms are regulated and control signalling could uncover their roles in pathology and reveal in which disease contexts their blockade could be most beneficial.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20379207     DOI: 10.1038/nrm2882

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  174 in total

Review 1.  Role of class II phosphoinositide 3-kinase in cell signalling.

Authors:  M Falasca; T Maffucci
Journal:  Biochem Soc Trans       Date:  2007-04       Impact factor: 5.407

2.  Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms.

Authors:  Roy M Katso; Olivier E Pardo; Andrea Palamidessi; Clemens M Franz; Marin Marinov; Angela De Laurentiis; Julian Downward; Giorgio Scita; Anne J Ridley; Michael D Waterfield; Alexandre Arcaro
Journal:  Mol Biol Cell       Date:  2006-06-14       Impact factor: 4.138

3.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

4.  Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing.

Authors:  Karin Reif; Klaus Okkenhaug; Takehiko Sasaki; Joseph M Penninger; Bart Vanhaesebroeck; Jason G Cyster
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

Review 5.  Phosphatidylinositol 3,5-bisphosphate and Fab1p/PIKfyve underPPIn endo-lysosome function.

Authors:  Stephen K Dove; Kangzhen Dong; Takafumi Kobayashi; Fay K Williams; Robert H Michell
Journal:  Biochem J       Date:  2009-04-01       Impact factor: 3.857

6.  Multiple cytokines activate phosphatidylinositol 3-kinase in hemopoietic cells. Association of the enzyme with various tyrosine-phosphorylated proteins.

Authors:  M R Gold; V Duronio; S P Saxena; J W Schrader; R Aebersold
Journal:  J Biol Chem       Date:  1994-02-18       Impact factor: 5.157

Review 7.  Rethinking phosphatidylinositol 3-monophosphate.

Authors:  Marco Falasca; Tania Maffucci
Journal:  Biochim Biophys Acta       Date:  2009-10-21

8.  Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.

Authors:  Evangelia A Papakonstanti; Olivier Zwaenepoel; Antonio Bilancio; Emily Burns; Gemma E Nock; Benjamin Houseman; Kevan Shokat; Anne J Ridley; Bart Vanhaesebroeck
Journal:  J Cell Sci       Date:  2008-11-25       Impact factor: 5.285

9.  The role of phosphoinositide 3-kinase C2alpha in insulin signaling.

Authors:  Marco Falasca; William E Hughes; Veronica Dominguez; Gianluca Sala; Florentia Fostira; Michelle Q Fang; Rosanna Cazzolli; Peter R Shepherd; David E James; Tania Maffucci
Journal:  J Biol Chem       Date:  2007-07-20       Impact factor: 5.157

Review 10.  Endosomal phosphoinositides and human diseases.

Authors:  Anne-Sophie Nicot; Jocelyn Laporte
Journal:  Traffic       Date:  2008-04-21       Impact factor: 6.215

View more
  638 in total

1.  A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.

Authors:  Sang Hyun Lee; George Poulogiannis; Saumyadipta Pyne; Shidong Jia; Lihua Zou; Sabina Signoretti; Massimo Loda; Lewis Clayton Cantley; Thomas M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Pharmacological profile of phosphatidylinositol 3-kinases and related phosphatidylinositols mediating endothelin(A) receptor-operated native TRPC channels in rabbit coronary artery myocytes.

Authors:  J Shi; M Ju; W A Large; A P Albert
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

3.  PI3Kα inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction.

Authors:  David Garcia-Galiano; Beatriz C Borges; Jose Donato; Susan J Allen; Nicole Bellefontaine; Mengjie Wang; Jean J Zhao; Kenneth M Kozloff; Jennifer W Hill; Carol F Elias
Journal:  JCI Insight       Date:  2017-12-07

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

5.  Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma.

Authors:  Marie Cumberbatch; Ximing Tang; Garry Beran; Sonia Eckersley; Xin Wang; Rebecca P A Ellston; Simon Dearden; Sabina Cosulich; Paul D Smith; Carmen Behrens; Edward S Kim; Xinying Su; Shuqiong Fan; Neil Gray; David P Blowers; Ignacio I Wistuba; Chris Womack
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

6.  A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.

Authors:  Jae-Hyeog Choi; Ki Hyang Kim; Kug-Hwan Roh; Hana Jung; Anbok Lee; Ji-Young Lee; Joo Yeon Song; Seung Jae Park; Ilhwan Kim; Won-Sik Lee; Su-Kil Seo; Il-Whan Choi; Yang-Xin Fu; Sung Su Yea; SaeGwang Park
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

Review 7.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

8.  mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.

Authors:  Stefan Thiem; Thomas P Pierce; Michelle Palmieri; Tracy L Putoczki; Michael Buchert; Adele Preaudet; Ryan O Farid; Chris Love; Bruno Catimel; Zhengdeng Lei; Steve Rozen; Veena Gopalakrishnan; Fred Schaper; Michael Hallek; Alex Boussioutas; Patrick Tan; Andrew Jarnicki; Matthias Ernst
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

9.  Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.

Authors:  Yvette M Carter; Selvi Kunnimalaiyaan; Herbert Chen; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

10.  Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.

Authors:  Charlotte E Edling; Federico Selvaggi; Ragheda Ghonaim; Tania Maffucci; Marco Falasca
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.